A new study published in the New England Journal of Medicine showed that once-weekly injectable semaglutide led to ...

The ‘Ozempic drug,’ semaglutide, has been found to reduce moderately severe pain caused by knee osteoarthritis and improve ...

Topline results were announced from a phase 3 clinical trial evaluating subcutaneous semaglutide in obesity and knee osteoarthritis.

Fewer patients experienced a first hospital admission for any indication and for serious adverse events while on semaglutide.

Researchers investigate the clinical efficacy of semaglutide in controlling urine albumin-to-creatinine ratio in overweight ...

Key Takeaways Tirzepatide may be more effective than semaglutide or liraglutide for weight loss, as it has a dual mechanism of action. Semaglutide has the longest half-life of the three, which may ...

Topline results were announced from a phase 3 clinical trial evaluating subcutaneous semaglutide in patients with MASH and liver fibrosis.

Its authors also investigated the effect of semaglutide dose sizes on adverse gastrointestinal effects for both subcutaneous injection and orally taken versions of the drug. These side effects ...

For individuals with obesity and knee osteoarthritis, once-weekly semaglutide yields greater reductions in body weight and ...

Semaglutide consumption almost doubles ... validated in obese/overweight and diabetic cohorts, with subcutaneous (usually 2.4 mg) injections administered weekly demonstrating generation-defining ...

Semaglutide met both primary endpoints in part 1 of ESSENCE. Topline results were announced from part 1 of a phase 3 clinical trial evaluating subcutaneous semaglutide in patients with metabolic ...